Bristol-myers Squibb Compnay

The General Hospital Corporation

Elena Getmanova

Lin Sun

Yan Chen

Ai Ching Lim

Michael Wittekind

Martin C Wright

Jochem Gokemeijer

Alan S Harris

Brian Seed

Edward F Fritsch

Alexander Kovtun

The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.

Libraries of modified fibronectin type III tenth domain-containing polypeptides

Inhibitors of type 2 vascular endothelial growth factor receptors

Disclosed herein are methods and compositions related to engineered fragments of the human transglutaminase-related protein family, described herein as engineered transglutaminase barrel proteins (ETBPs), that have utility as high affinity, high selectivity target-binding proteins offering advantages as antibody equivalents for therapeutic, analytical, manufacturing and research purposes. ETBPs differ from naturally occurring human transglutaminase fragments by the addition, deletion, replacement and/or substitution of the naturally occurring amino acid sequence. ETBPs can be easily expressed in prokaryotic cells and in many cases can be purified by a simple solubilization and precipitation method.

Engineered transglutaminase barrel proteins

Methods of inhibiting type 2 vascular endothelial growth factor receptors using polypeptides

Nucleic acid encoding 10FN3 polypeptide inhibitors of Type 2 vascular endothelial growth factor receptors

Pharmacokinetic modulation and compositions for modified FN3 polypeptides

Growing community of inventors

Lexington, MA, United States of America

Elena Getmanova